Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun 3;8(1):8.
doi: 10.1186/1559-0275-8-8.

Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia

Affiliations

Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia

Jacob Nersting et al. Clin Proteomics. .

Abstract

Predicting the response to medical therapy and subsequently individualizing the treatment to increase efficacy or reduce toxicity has been a longstanding clinical goal. Not least within oncology, where many patients fail to be cured, and others are treated to or beyond the limit of acceptable toxicity, an individualized therapeutic approach is indicated. The mapping of the human genome and technological developments in DNA sequencing, gene expression profiling, and proteomics have raised the expectations for implementing genotype-phenotype data into the clinical decision process, but also multiplied the complex interaction of genetic and other laboratory parameters that can be used for therapy adjustments. Thus, with the advances in the laboratory techniques, post laboratory issues have become major obstacles for treatment individualization. Many of these challenges have been illustrated by studies involving childhood acute lymphoblastic leukemia (ALL), where each patient may receive up to 13 different anticancer agents over a period of 2-3 years. The challenges include i) addressing important, but low-frequency outcomes, ii) difficulties in interpreting the impact of single drug or single gene response data that often vary across treatment protocols, iii) combining disease and host genomics with outcome variations, and iv) physicians' reluctance in implementing potentially useful genotype and phenotype data into clinical practice, since unjustified downward or upward dose adjustments could increase the of risk of relapse or life-threatening complications. In this review we use childhood ALL therapy as a model and discuss these issues, and how they may be addressed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The applied therapy affects disease and patient leading to treatment failure or cure, and side effects, respectively. This in term may lead to therapy changes. For drugs with high therapeutic indices, therapy modifications is mainly determined by the response of the disease, whereas for drugs with low therapeutic indices, feedback through both the therapy-patient axis and the therapy-patient axis is likely to modify the therapy. Patient and disease interact directly via immune responses, bone marrow stroma support of leukemia, and suppression of hematopoesis etc. In addition to affecting the therapy-patient interaction, the patient's pharmacogenetic profile affects the therapy-disease axis through its effect on drug clearance, metabolism, distribution etc.

References

    1. Bates S. Progress towards personalized medicine. Drug Discov Today. 2010;15:115–120. doi: 10.1016/j.drudis.2009.11.001. - DOI - PubMed
    1. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58:521–590. doi: 10.1124/pr.58.3.6. - DOI - PubMed
    1. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30:831–849. doi: 10.1097/MPH.0b013e3181868570. - DOI - PubMed
    1. Lund B, Åsberg A, Heyman M. et al.Risk Factors for Treatment Related Mortality in Childhood Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2011;56:551–9. doi: 10.1002/pbc.22719. - DOI - PubMed
    1. Schmiegelow K, Bretton-Meyer U. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Leukemia. 2001;15:74–79. doi: 10.1038/sj.leu.2401986. - DOI - PubMed

LinkOut - more resources